Next 10 |
2024-05-15 09:45:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. The U.S. equity market continued to ra...
2024-05-15 09:10:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the first quarter of 2024, Aristot...
2024-05-15 09:00:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. U.S. economic growth remained positive...
2024-05-08 18:43:24 ET Adaptive Biotechnologies (NASDAQ: ADPT) , a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the cure for the stock market blahs on Wednesday. The commercia...
2024-05-07 20:59:07 ET Adaptive Biotechnologies Corporation. (ADPT) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Piskel - CFO Susan Bobulsky - Senior Vice Pr...
2024-05-07 16:46:31 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: A Post Earnings Assessment Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript Adaptive Biotechnologies Corporation 2023 Q4 - Results - Earnings Call Presentati...
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-06 17:35:57 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: A Post Earnings Assessment Adaptive Biotechnologies announces conclusion of strategic review, expects Q1 revenue between $41M and $43M Adaptive Biotechnologies GAAP EPS of -$0.48 misses...
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financia...
News, Short Squeeze, Breakout and More Instantly...
Adaptive Biotechnologies Corporation Company Name:
ADPT Stock Symbol:
NASDAQ Market:
Adaptive Biotechnologies Corporation Website:
2024-05-08 18:43:24 ET Adaptive Biotechnologies (NASDAQ: ADPT) , a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the cure for the stock market blahs on Wednesday. The commercia...
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...